| Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer M Zou, R Toivanen, A Mitrofanova, N Floch, S Hayati, Y Sun, ... Cancer discovery 7 (7), 736-749, 2017 | 327 | 2017 |
| Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS … U Platzbecker, MG Della Porta, V Santini, AM Zeidan, RS Komrokji, ... The Lancet 402 (10399), 373-385, 2023 | 58 | 2023 |
| Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia LW Dillon, S Hayati, GW Roloff, I Tunc, M Pirooznia, A Mitrofanova, ... Haematologica 104 (2), 297, 2019 | 37 | 2019 |
| Integrative (epi) genomic analysis to predict response to androgen-deprivation therapy in prostate cancer S Panja, S Hayati, NJ Epsi, JS Parrott, A Mitrofanova EBioMedicine 31, 110-121, 2018 | 19 | 2018 |
| Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-resistant Prostate Cancer. Cancer Discov. 2017. doi: 10.1158/2159-8290 M Zou, R Toivanen, A Mitrofanova, N Floc’h, S Hayati, Y Sun, ... CD-16-1174, 0 | 4 | |
| Predictive Biomarkers of Response to Luspatercept in Patients with Myelofibrosis-(MF) Associated Anemia: Biomarker Analysis from the ACE-536-MF-001 Study D Jeyaraju, S Hayati, N Marsousi, AT Gerds, F Passamonti, F Sanabria, ... Blood 142, 6330, 2023 | 1 | 2023 |
| Comparison of gene expression profiling platforms: translatability of tumor inflammation gene signatures E Anguiano, K Desai, S Hayati, PM Szabo, S Pant, L Wang, N Zhang Cancer Res. 80, 1997-1997, 2020 | 1 | 2020 |
| Luspatercept Modulates Inflammation in the Bone Marrow, Restores Effective Erythropoiesis/Hematopoiesis, and Provides Sustained Clinical Benefit Versus Epoetin Alfa (EA … S Hayati, AM Zeidan, G Garcia-Manero, U Platzbecker, A Ahsan, ... Blood 142, 1845, 2023 | | 2023 |
| Clonal Hematopoiesis-Related Mutations Are Associated with Favorable Clinical Benefit Following Luspatercept Treatment in Patients with Lower-Risk Myelodysplastic Syndromes: A … M Hasan, S Vodala, S Hayati, G Garcia-Manero, AK Gandhi, ... Blood 142, 3214, 2023 | | 2023 |
| Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker … D Jeyaraju, S Hayati, J Wang, CN Harrison, JJ Kiladjian, C Hernandez, ... Blood 142, 4526, 2023 | | 2023 |
| Impact of Genomic Landscape and Mutational Burden on Primary Endpoint Responses in the COMMANDS Study RS Komrokji, MU Guerrero, G Garcia-Manero, AM Zeidan, U Platzbecker, ... Blood 142, 4591, 2023 | | 2023 |
| POSTER: MDS-071 Luspatercept Restores Effective Erythropoiesis and Provides Superior and Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase … U Platzbecker, S Hayati, A Ahsan, A Verma, S Aluri, S Rose, A Gandhi, ... Clinical Lymphoma Myeloma and Leukemia 23, S184, 2023 | | 2023 |
| MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS … G Garcia-Manero, U Platzbecker, V Santini, AM Zeidan, P Fenaux, ... Clinical Lymphoma Myeloma and Leukemia 23, S355-S356, 2023 | | 2023 |
| POSTER: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes … G Garcia-Manero, U Platzbecker, V Santini, AM Zeidan, P Fenaux, ... Clinical Lymphoma Myeloma and Leukemia 23, S184, 2023 | | 2023 |
| Oral Abstract: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic … G Garcia-Manero, U Platzbecker, V Santini, AM Zeidan, P Fenaux, ... Clinical Lymphoma Myeloma and Leukemia 23, S145, 2023 | | 2023 |
| MDS-071 Luspatercept Restores Effective Erythropoiesis and Provides Superior and Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase III … U Platzbecker, S Hayati, A Ahsan, A Verma, S Aluri, S Rose, A Gandhi, ... Clinical Lymphoma Myeloma and Leukemia 23, S353-S354, 2023 | | 2023 |
| P697: DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY S Aluri, A Ahsan, S Hayati, M Ugidos, P Shah, K Lizotte, S Chakraborty, ... HemaSphere 7 (S3), e8463948, 2023 | | 2023 |
| P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY U Platzbecker, S Hayati, A Ahsan, A Verma, S Aluri, S Rose, A Gandhi, ... HemaSphere 7 (S3), e379048e, 2023 | | 2023 |
| P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS D Jeyaraju, S Hayati, A Polonskaia, A Browne, A Risueño, P Hagner, ... HemaSphere 7 (S3), e975395e, 2023 | | 2023 |
| S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA … MG Della Porta, U Platzbecker, V Santini, AM Zeidan, P Fenaux, ... HemaSphere 7, e999540c, 2023 | | 2023 |
Andrea CalifanoColumbia Verified email at c2b2.columbia.edu
